MiNK Therapeutics, Inc.

MiNK Therapeutics is a clinical-stage biopharmaceutical company developing allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases. Its platform is built to manufacture scalable, reproducible cell therapies, with a pipeline that includes native and engineered iNKT programs such as agenT-797, MiNK-215, and MiNK-413.

1.06

1.06

— MiNK Therapeutics, Inc.
%
Clinical-stage cell therapy candidates70% Includes lead and pipeline iNKT programs being advanced through preclinical and clinical development.
Platform and manufacturing capabilities20% Includes proprietary methods for scalable, reproducible off-the-shelf iNKT cell production.
Collaborative discovery programs10% Includes partnered TCR discovery and other research collaborations that expand the pipeline.

MiNK does not sell commercial products broadly; its primary counterparties are clinical investigators, regulators, and...

  • Oncology treatment centersprimary

    Hospitals and cancer centers would administer iNKT therapies in future commercialization, especially for solid tumors and hematologic cancers.

  • Clinical trial investigatorsprimary

    Academic and specialty investigators run early-stage studies that generate safety, persistence, and efficacy data.

  • Biopharma partnerssecondary

    Partners may collaborate on discovery, licensing, or co-development to broaden the pipeline and share risk.

  • Regulatory agenciesprimary

    FDA and other agencies are key gatekeepers for IND clearance and later clinical and commercial approvals.

MiNK is headquartered in the United States and its development work is centered there, including research,...

  • •United States is the core operating and development base
  • •Research, manufacturing, and regulatory work are U.S.-centered
  • •UK R&D tax credit suggests some foreign tax exposure
  • •International collaboration expands scientific reach
  • •No country revenue split was disclosed in the excerpts

MiNK’s strategy is to advance a differentiated allogeneic iNKT platform into clinical development while keeping...

01
Submit IND for MiNK-215short-term

IND clearance is the key step to move a lead solid-tumor program into human testing.

02
Advance engineered iNKT pipelinemedium-term

MiNK-413 and other engineered programs broaden the platform beyond the lead asset.

03
Scale manufacturing and reproducibilitymedium-term

Off-the-shelf cell therapy economics depend on consistent, scalable production.

04
Pursue collaborations and licensingshort-term

Partnerships can extend the pipeline and reduce capital intensity for a small biotech.

MiNK is exposed to the high failure rate of clinical-stage biotech, where preclinical promise may not translate into...

high

Clinical development failure

Preclinical activity may not translate into safe or effective human outcomes.

Scope
Lead and pipeline iNKT programs
Materiality
high
high

Regulatory delay or rejection

IND submission, trial initiation, and later approvals are uncertain and capital intensive.

Scope
MiNK-215 and future programs
Materiality
high
high

Financing and dilution risk

The company has ongoing operating losses and will likely need external capital.

Scope
General corporate funding
Materiality
high
medium

Dependence on Agenus

Agenus provides support services, facilities, and licensed IP that are important to operations.

Scope
Operations and governance
Materiality
high
medium

Manufacturing and scale-up risk

Cell therapy economics depend on reliable, reproducible production at scale.

Scope
Off-the-shelf iNKT platform
Materiality
high
R&D expense timing
Quarterly comparability can be volatile
Allocated services from Agenus
Can shift G&A and R&D expense levels
Refundable UK R&D tax credit
Affects non-operating income
Liability forgiveness
Can temporarily improve reported R&D

INTENSITY THERAPEUTICS, INC.

INTS · Biological Products, (No Diagnostic Substances)

Context Therapeutics Inc.

CNTX · Pharmaceutical Preparations

Marker Therapeutics, Inc.

MRKR · Pharmaceutical Preparations

Nkarta, Inc.

NKTX · Pharmaceutical Preparations

Inhibikase Therapeutics, Inc.

IKT · Biological Products, (No Diagnostic Substances)

NEKTAR THERAPEUTICS

NKTR · Pharmaceutical Preparations

: 28/04/2026